

# Bernard Hirschel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10376379/publications.pdf>

Version: 2024-02-01

156  
papers

13,700  
citations

16437

64  
h-index

21521

114  
g-index

156  
all docs

156  
docs citations

156  
times ranked

10143  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic Variation in IL28B Is Associated With Chronic Hepatitis C and Treatment Failure: A Genome-Wide Association Study. <i>Gastroenterology</i> , 2010, 138, 1338-1345.e7.	0.6	1,056
2	Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. <i>Lancet, The</i> , 1999, 353, 863-868.	6.3	894
3	Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. <i>Aids</i> , 2010, 24, 1243-1250.	1.0	592
4	Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. <i>BMJ: British Medical Journal</i> , 1997, 315, 1194-1199.	2.4	528
5	AIDS-Related Opportunistic Illnesses Occurring After Initiation of Potent Antiretroviral Therapy. <i>JAMA - Journal of the American Medical Association</i> , 1999, 282, 2220.	3.8	416
6	CD4 T-Lymphocyte Recovery in Individuals With Advanced HIV-1 Infection Receiving Potent Antiretroviral Therapy for 4 Years<subtitle>The Swiss HIV Cohort Study</subtitle>. <i>Archives of Internal Medicine</i> , 2003, 163, 2187.	4.3	344
7	Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. <i>Lancet, The</i> , 2001, 358, 1322-1327.	6.3	317
8	Characteristics, Determinants, and Clinical Relevance of CD4 T Cell Recovery to <500 Cells/ÅL in HIV Type 1-Infected Individuals Receiving Potent Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2005, 41, 361-372.	2.9	285
9	HIV rebounds from latently infected cells, rather than from continuing low-level replication. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 16725-16730.	3.3	273
10	Discontinuation of Primary Prophylaxis against <i>Pneumocystis carinii</i> Pneumonia in HIV-1-Infected Adults Treated with Combination Antiretroviral Therapy. <i>New England Journal of Medicine</i> , 1999, 340, 1301-1306.	13.9	271
11	CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. <i>Lancet, The</i> , 2006, 368, 459-465.	6.3	233
12	Factors Associated with the Incidence of Type 2 Diabetes Mellitus in HIV-Infected Participants in the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2007, 45, 111-119.	2.9	233
13	Immunological recovery and antiretroviral therapy in HIV-1 infection. <i>Lancet Infectious Diseases, The</i> , 2006, 6, 280-287.	4.6	220
14	Unsafe Sex and Increased Incidence of Hepatitis C Virus Infection among HIV-Infected Men Who Have Sex with Men: The Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2005, 41, 395-402.	2.9	203
15	Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 13747-13752.	3.3	199
16	A Controlled Study of Inhaled Pentamidine for Primary Prevention of <i>Pneumocystis carinii</i> Pneumonia. <i>New England Journal of Medicine</i> , 1991, 324, 1079-1083.	13.9	185
17	Impact of drug resistance mutations on virologic response to salvage therapy. <i>Aids</i> , 1999, 13, F17-F21.	1.0	180
18	Molecular Epidemiology Reveals Long-Term Changes in HIV Type 1 Subtype B Transmission in Switzerland. <i>Journal of Infectious Diseases</i> , 2010, 201, 1488-1497.	1.9	172

#	ARTICLE	IF	CITATIONS
19	Correlates of Self-Reported Nonadherence to Antiretroviral Therapy in HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2006, 41, 385-392.	0.9	156
20	A Prospective Trial of Structured Treatment Interruptions in Human Immunodeficiency Virus Infection. <i>Archives of Internal Medicine</i> , 2003, 163, 1220.	4.3	153
21	A Controlled Study of Early Neurologic Abnormalities in Men with Asymptomatic Human Immunodeficiency Virus Infection. <i>New England Journal of Medicine</i> , 1990, 323, 864-870.	13.9	150
22	Fatal Infection with a Novel, Unidentified Mycobacterium in a Man with the Acquired Immunodeficiency Syndrome. <i>New England Journal of Medicine</i> , 1990, 323, 109-113.	13.9	146
23	A Randomized Trial of Simplified Maintenance Therapy with Abacavir, Lamivudine, and Zidovudine in Human Immunodeficiency Virus Infection. <i>Journal of Infectious Diseases</i> , 2002, 185, 1251-1260.	1.9	132
24	HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. <i>Aids</i> , 2009, 23, 929-939.	1.0	130
25	A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. <i>Aids</i> , 1998, 12, F71-77.	1.0	128
26	Treatment Modification in Human Immunodeficiency Virus-Infected Individuals Starting Combination Antiretroviral Therapy Between 2005 and 2008. <i>Archives of Internal Medicine</i> , 2010, 170, 57.	4.3	127
27	Ambiguous Nucleotide Calls From Population-based Sequencing of HIV-1 are a Marker for Viral Diversity and the Age of Infection. <i>Clinical Infectious Diseases</i> , 2011, 52, 532-539.	2.9	127
28	Abnormalities of Body Fat Distribution in HIV-Infected Persons Treated With Antiretroviral Drugs. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2002, 31, 50-55.	0.9	121
29	Emergence of Minor Populations of Human Immunodeficiency Virus Type 1 Carrying the M184V and L90M Mutations in Subjects Undergoing Structured Treatment Interruptions. <i>Journal of Infectious Diseases</i> , 2003, 188, 1433-1443.	1.9	121
30	Emergence of HIV-1 Drug Resistance in Previously Untreated Patients Initiating Combination Antiretroviral Treatment<sub>title</sub>>A Comparison of Different Regimen Types<sub>title</sub>>. <i>Archives of Internal Medicine</i> , 2007, 167, 1782.	4.3	116
31	Reducing Tuberculosis Incidence by Tuberculin Skin Testing, Preventive Treatment, and Antiretroviral Therapy in an Area of Low Tuberculosis Transmission. <i>Clinical Infectious Diseases</i> , 2007, 44, 94-102.	2.9	114
32	Loss of antibodies against hepatitis C virus in HIV-seropositive intravenous drug users. <i>Aids</i> , 1990, 4, 1275-1278.	1.0	109
33	Tenofovir Use is associated with a Reduction in Calculated Glomerular Filtration Rates in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2007, 12, 1165-1174.	0.6	109
34	Phylogenetic Approach Reveals That Virus Genotype Largely Determines HIV Set-Point Viral Load. <i>PLoS Pathogens</i> , 2010, 6, e1001123.	2.1	108
35	Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. <i>Aids</i> , 2002, 16, 1967-1969.	1.0	107
36	Switch to Unusual Amino Acids at Codon 215 of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Gene in Seroconvertors Infected with Zidovudine-Resistant Variants. <i>Journal of Virology</i> , 1998, 72, 3520-3523.	1.5	107

#	ARTICLE	IF	CITATIONS
37	Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 Å– 106/l. <i>Aids</i> , 2002, 16, 1371-1381.	1.0	105
38	Modeling the Influence ofAPOC3, APOE,andTNFPolymorphisms on the Risk of Antiretroviral Therapyâ€“Associated Lipid Disorders. <i>Journal of Infectious Diseases</i> , 2005, 191, 1419-1426.	1.9	105
39	Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population. <i>Lancet, The</i> , 2003, 362, 877-878.	6.3	101
40	Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. <i>Aids</i> , 2010, 24, 2347-2354.	1.0	101
41	Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir. <i>Aids</i> , 1997, 11, F95-F99.	1.0	99
42	The impact of transmission clusters on primary drug resistance in newly diagnosed HIV-1 infection. <i>Aids</i> , 2009, 23, 1415-1423.	1.0	96
43	Durability and Outcome of Initial Antiretroviral Treatments Received during 2000â€“2005 by Patients in the Swiss HIV Cohort Study. <i>Journal of Infectious Diseases</i> , 2008, 197, 1685-1694.	1.9	95
44	Lipid Profiles for Antiretroviral-Naive Patients Starting Pi- and Nnrti-Based Therapy in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2005, 10, 585-591.	0.6	95
45	Prevalence and incidence rate of HIV, hepatitis B and C among drug users on methadone maintenance treatment in Geneva between 1988 and 1995. <i>Aids</i> , 1998, 12, 2059-2066.	1.0	93
46	Longitudinal Analysis of Patterns and Predictors of Changes in Self-Reported Adherence to Antiretroviral Therapy: Swiss HIV Cohort Study. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2010, 54, 197-203.	0.9	91
47	Decay of cell-associated HIV-1 DNA correlates with residual replication in patients treated during acute HIV-1 infection. <i>Aids</i> , 2000, 14, 2805-2812.	1.0	89
48	The role of compartment penetration in PI-Monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial. <i>Aids</i> , 2007, 21, 1309-1315.	1.0	89
49	Association of Pharmacogenetic Markers with Premature Discontinuation of First-line Anti-HIV Therapy: An Observational Cohort Study. <i>Journal of Infectious Diseases</i> , 2011, 203, 246-257.	1.9	89
50	Frequency and Determinants of Unprotected Sex among HIVâ€“Infected Persons: The Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2010, 51, 1314-1322.	2.9	83
51	HIV RNA in plasma rebounds within days during structured treatment interruptions. <i>Aids</i> , 2003, 17, 195-199.	1.0	82
52	Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial. <i>Aids</i> , 2003, 17, F33-F37.	1.0	78
53	Effect of Early Antiretroviral Therapy during Primary HIV-1 Infection on Cell-Associated HIV-1 Dna and Plasma HIV-1 Rna. <i>Antiviral Therapy</i> , 2011, 16, 535-545.	0.6	77
54	Migrants from Sub-Saharan Africa in the Swiss HIV Cohort Study. <i>Aids</i> , 2003, 17, 2237-2244.	1.0	76

#	ARTICLE	IF	CITATIONS
55	Quantifiable cytotoxic T lymphocyte responses and HLA-related risk of progression to AIDS. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 12266-12270.	3.3	76
56	A Prospective, Randomized Trial of Structured Treatment Interruption for Patients with Chronic HIV Type 1 Infection. Clinical Infectious Diseases, 2005, 40, 594-600.	2.9	76
57	Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia. Aids, 2000, 14, 243-249.	1.0	75
58	Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy. Pharmacogenetics and Genomics, 2007, 17, 755-764.	0.7	74
59	The Role of Migration and Domestic Transmission in the Spread of HIV-1 Non-B Subtypes in Switzerland. Journal of Infectious Diseases, 2011, 204, 1095-1103.	1.9	74
60	Proviral HIV-DNA predicts viral rebound and viral setpoint after structured treatment interruptions. Aids, 2004, 18, 1951-1953.	1.0	73
61	Tenofovir use is Associated with an Increase in Serum Alkaline Phosphatase in the Swiss HIV Cohort Study. Antiviral Therapy, 2008, 13, 1077-1082.	0.6	71
62	Hypogonadism in HIV-1-Infected Men is common and does not resolve during antiretroviral therapy. Antiviral Therapy, 2007, 12, 261-266.	0.6	69
63	Progress and Problems in the Fight against AIDS. New England Journal of Medicine, 1998, 338, 906-908.	13.9	68
64	Prevalence of Unsafe Sexual Behavior Among HIV-Infected Individuals: The Swiss HIV Cohort Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 33, 494-499.	0.9	66
65	A randomized double-blind controlled study of 6 months of oral nutritional supplementation with arginine and Î©-3 fatty acids in HIV-infected patients. Aids, 1998, 12, 53-63.	1.0	65
66	Infrequent Transmission of HIV-1 Drug-Resistant Variants. Antiviral Therapy, 2004, 9, 375-384.	0.6	59
67	Cellular Viral Rebound after Cessation of Potent Antiretroviral Therapy Predicted by Levels of Multiply Spliced HIV-1 RNA Encoding nef. Journal of Infectious Diseases, 2004, 190, 1979-1988.	1.9	56
68	Improved Virological Outcome in White Patients Infected With HIV-1 Non-B Subtypes Compared to Subtype B. Clinical Infectious Diseases, 2011, 53, 1143-1152.	2.9	53
69	Prognostic Value of Viremia in Patients with Long-Standing Human Immunodeficiency Virus Infection. Journal of Infectious Diseases, 1996, 173, 1388-1393.	1.9	50
70	Neuro-otological Manifestations in Different Stages of HIV Infection. Acta Oto-Laryngologica, 1991, 111, 515-521.	0.3	49
71	Late Presentation of HIV-Infected Individuals. Antiviral Therapy, 2007, 12, 841-851.	0.6	49
72	14th Conference on Retroviruses and Opportunistic Infections (CROI 2007). Future HIV Therapy, 2007, 1, 13-16.	0.5	47

#	ARTICLE	IF	CITATIONS
73	Impact of highly active antiretroviral therapy on the molecular epidemiology of newly diagnosed HIV infections. <i>Aids</i> , 2012, 26, 2079-2086.	1.0	47
74	A new era of antiretroviral drug toxicity. <i>Antiviral Therapy</i> , 2009, 14, 165-179.	0.6	47
75	Stable partnership and progression to AIDS or death in HIV infected patients receiving highly active antiretroviral therapy: Swiss HIV cohort study. <i>BMJ: British Medical Journal</i> , 2004, 328, 15-0.	2.4	46
76	Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point. <i>Blood</i> , 2004, 104, 1784-1792.	0.6	46
77	CD4 <sup>+</sup> T Cell Count Recovery in HIV Type 1 Infected Patients Is Independent of Class of Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2008, 47, 1093-1101.	2.9	46
78	Early Antiretroviral Therapy During Primary HIV-1 Infection Results in a Transient Reduction of the Viral Setpoint upon Treatment Interruption. <i>PLoS ONE</i> , 2011, 6, e27463.	1.1	46
79	Self-reported alcohol consumption and its association with adherence and outcome of antiretroviral therapy in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2009, 14, 349-357.	0.6	45
80	Human Immunodeficiency Virus-Specific CD8 <sup>+</sup> T-Cell Responses Do Not Predict Viral Growth and Clearance Rates during Structured Intermittent Antiretroviral Therapy. <i>Journal of Virology</i> , 2002, 76, 10169-10176.	1.5	43
81	Long-Term Trends of HIV Type 1 Drug Resistance Prevalence among Antiretroviral Treatment-Experienced Patients in Switzerland. <i>Clinical Infectious Diseases</i> , 2009, 48, 979-987.	2.9	43
82	Impact of occasional short interruptions of HAART on the progression of HIV infection: results from a cohort study. <i>Aids</i> , 2002, 16, 747-755.	1.0	40
83	Low Human Immunodeficiency Virus Envelope Diversity Correlates with Low In Vitro Replication Capacity and Predicts Spontaneous Control of Plasma Viremia after Treatment Interruptions. <i>Journal of Virology</i> , 2005, 79, 9026-9037.	1.5	40
84	Failure to Detect Xenotropic Murine Leukemia Virus-Related Virus in Blood of Individuals at High Risk of Blood-Borne Viral Infections. <i>Journal of Infectious Diseases</i> , 2010, 202, 1482-1485.	1.9	40
85	Genetic polymorphism of CCR5 gene and HIV disease: The heterozygous (CCR5 <sup>Δ32</sup> ) genotype is neither essential nor sufficient for protection against disease progression. <i>European Journal of Immunology</i> , 1997, 27, 3223-3227.	1.6	39
86	Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy The Swiss HIV Cohort Study. <i>Aids</i> , 2001, 15, 1793-1800.	1.0	39
87	Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score. <i>Aids</i> , 2007, 21, 1867-1875.	1.0	38
88	Contribution of Genome-Wide Significant Single-Nucleotide Polymorphisms and Antiretroviral Therapy to Dyslipidemia in HIV-Infected Individuals. <i>Circulation: Cardiovascular Genetics</i> , 2009, 2, 621-628.	5.1	38
89	Drug Resistance Mutations during Structured Treatment Interruptions. <i>Antiviral Therapy</i> , 2003, 8, 411-415.	0.6	37
90	Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients. <i>Aids</i> , 2000, 14, 791-799.	1.0	36

#	ARTICLE	IF	CITATIONS
91	Factors Associated with the Emergence of K65R in Patients with HIV-1 Infection Treated with Combination Antiretroviral Therapy Containing Tenofovir. <i>Clinical Infectious Diseases</i> , 2008, 46, 1299-1309.	2.9	35
92	Adverse Events to Antiretrovirals in the Swiss HIV Cohort Study: Effect on Mortality and Treatment Modification. <i>Antiviral Therapy</i> , 2007, 12, 1157-1164.	0.6	35
93	Eligibility for and Outcome of Hepatitis C Treatment of HIV-Coinfected Individuals in Clinical Practice: The Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2006, 11, 131-142.	0.6	35
94	Relevance of HIV-1-Specific CD4+ Helper T-Cell Responses During Structured Treatment Interruptions in Patients With CD4+ T-Cell Nadir Above 400/mm <sup>3</sup> . <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2004, 36, 791-799.	0.9	34
95	Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine--a Staccato trial substudy. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 61, 1340-1343.	1.3	34
96	Interruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and death. <i>Aids</i> , 2011, 25, 441-451.	1.0	34
97	Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection. <i>Aids</i> , 2008, 22, 152-154.	1.0	33
98	Incidence of HIV-1 Drug Resistance Among Antiretroviral Treatment-naïve Individuals Starting Modern Therapy Combinations. <i>Clinical Infectious Diseases</i> , 2012, 54, 131-140.	2.9	32
99	Behavioural changes in intravenous drug users in Geneva. <i>Aids</i> , 1990, 4, 657-660.	1.0	31
100	Switching from protease inhibitors to efavirenz: differences in efficacy and tolerance among risk groups: a case-control study from the Swiss HIV Cohort. <i>Aids</i> , 2002, 16, 381-385.	1.0	31
101	Is unsafe sexual behaviour increasing among HIV-infected individuals?. <i>Aids</i> , 2004, 18, 1707-1714.	1.0	31
102	Long-term hydroxyurea in combination with didanosine and stavudine for the treatment of HIV-1 infection. <i>Aids</i> , 2000, 14, 2145-2151.	1.0	30
103	HIV treatment for prevention. <i>Journal of the International AIDS Society</i> , 2011, 14, 28-28.	1.2	30
104	The role of CFTR and SPINK-1 mutations in pancreatic disorders in HIV-positive patients. <i>Aids</i> , 2004, 18, 1521-1527.	1.0	29
105	Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir. <i>Aids</i> , 2005, 19, 1987-1994.	1.0	29
106	Homozygosity Is Associated with an Impaired CD4 T Cell Recovery after Initiation of Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2008, 46, 1921-1925.	2.9	28
107	Improved sensitivity of an interferon-gamma release assay (T-SPOT.TB) in combination with tuberculin skin test for the diagnosis of latent tuberculosis in the presence of HIV co-infection. <i>BMC Infectious Diseases</i> , 2011, 11, 319.	1.3	28
108	Virus Burden in Lymph Nodes and Blood of Subjects with Primary Human Immunodeficiency Virus Type 1 Infection on Bitherapy. <i>Journal of Infectious Diseases</i> , 1998, 177, 1497-1501.	1.9	27

#	ARTICLE	IF	CITATIONS
109	Association between the Rate of CD4+T Cell Decrease and the Year of Human Immunodeficiency Virus (HIV) Type 1 Seroconversion among Persons Enrolled in the Swiss HIV Cohort Study. <i>Journal of Infectious Diseases</i> , 1999, 180, 1803-1808.	1.9	27
110	No change in calculated creatinine clearance after tenofovir initiation among Thai patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 59, 1034-1037.	1.3	27
111	CERVICAL LYMPHADENITIS CAUSED BY MYCOBACTERIUM GENAVENSE IN A HEALTHY CHILD. <i>Pediatric Infectious Disease Journal</i> , 1996, 15, 269-270.	1.1	27
112	CD4 <sup>+</sup> T-Cell Count Increase in HIV-1-Infected Patients with Suppressed Viral Load Within 1 year after start of antiretroviral therapy. <i>Antiviral Therapy</i> , 2007, 12, 889-898.	0.6	27
113	Impact of Single Nucleotide Polymorphisms and of Clinical Risk Factors on New Onset Diabetes Mellitus in HIV-Infected Individuals. <i>Clinical Infectious Diseases</i> , 2010, 51, 1090-1098.	2.9	26
114	Blood and charcoal added to acidified agar media promote the growth of <i>Mycobacterium genavense</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 1999, 34, 45-50.	0.8	25
115	Long-Term Efficacy and Safety of First-Line Therapy with Once-Daily Saquinavir/Ritonavir. <i>Antiviral Therapy</i> , 2008, 13, 375-380.	0.6	25
116	The Prevalence of Erectile Dysfunction and Its Association with Antiretroviral Therapy in HIV-Infected Men: The Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2013, 18, 337-344.	0.6	24
117	HIV-1 p24 May Persist During Long-Term Highly Active Antiretroviral Therapy, Increases Little During Short Treatment Breaks, and Its Rebound After Treatment Stop Correlates With CD4+ T Cell Loss. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2005, 40, 250-256.	0.9	23
118	Viral Suppression Rates in Salvage Treatment With Raltegravir Improved With the Administration of Genotypic Partially Active or Inactive Nucleoside/Tide Reverse Transcriptase Inhibitors. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 57, 24-31.	0.9	23
119	Shifts in Cell-Associated HIV-1 Rna but Not in Episomal HIV-1 Dna Correlate with New Cycles of HIV-1 Infection <i>in vivo</i> . <i>Antiviral Therapy</i> , 2003, 8, 97-104.	0.6	23
120	A Prospective Study of Efficacy and Safety of Once-Daily Saquinavir/Ritonavir plus Two Nucleoside Reverse Transcriptase Inhibitors in Treatment-Naive Thai Patients. <i>Antiviral Therapy</i> , 2005, 10, 761-767.	0.6	23
121	Biphasic decline of CD4 cell count during scheduled treatment interruptions. <i>Aids</i> , 2005, 19, 439-441.	1.0	22
122	A controlled trial of granulocyte macrophage-colony stimulating factor during interruption of HAART. <i>Aids</i> , 2003, 17, 1487-1492.	1.0	21
123	A Comparison of Initial Antiretroviral Therapy in the Swiss HIV Cohort Study and the Recommendations of the International AIDS Society-USA. <i>PLoS ONE</i> , 2011, 6, e27903.	1.1	21
124	The Impact of Combination Antiretroviral Therapy and its Interruption on Anxiety, Stress, Depression and Quality of Life in Thai Patients. <i>Open AIDS Journal</i> , 2009, 3, 38-45.	0.1	20
125	Adverse events to antiretrovirals in the Swiss HIV Cohort Study: effect on mortality and treatment modification. <i>Antiviral Therapy</i> , 2007, 12, 1157-64.	0.6	20
126	Micro-Structural Brain Alterations in Aviremic HIV+ Patients with Minor Neurocognitive Disorders: A Multi-Contrast Study at High Field. <i>PLoS ONE</i> , 2013, 8, e72547.	1.1	19



#	ARTICLE	IF	CITATIONS
127	Seasonal incidence of <i>Pneumocystis carinii</i> pneumonia. <i>Lancet, The</i> , 1992, 339, 1182.	6.3	18
128	Is it smart to continue to study treatment interruptions?. <i>Aids</i> , 2009, 23, 757-759.	1.0	18
129	Impact of Previous Virological Treatment Failures and Adherence on the Outcome of Antiretroviral Therapy in 2007. <i>PLoS ONE</i> , 2009, 4, e8275.	1.1	18
130	Antiretroviral treatment during pregnancy. <i>Aids</i> , 2008, 22, 2323-2330.	1.0	17
131	L-ornithine $\hat{\pm}$ ketoglutarate in HIV infection: effects on muscle, gastrointestinal, and immune functions. <i>Nutrition</i> , 2004, 20, 515-520.	1.1	15
132	Neurocognitive impairment in patients randomized to second-line lopinavir/ritonavir-based antiretroviral therapy vs. lopinavir/ritonavir monotherapy. <i>Journal of NeuroVirology</i> , 2012, 18, 479-487.	1.0	15
133	Increased mortality after a first myocardial infarction in human immunodeficiency virus-infected patients; a nested cohort study. <i>AIDS Research and Therapy</i> , 2015, 12, 4.	0.7	15
134	Absence of Resistance Mutations in Antiretroviral-Naive Patients Treated with Ritonavir-Boosted Saquinavir. <i>Antiviral Therapy</i> , 2006, 11, 631-636.	0.6	15
135	Supervised interruptions of antiretroviral therapy. <i>Aids</i> , 2002, 16, S157-S169.	1.0	14
136	Diagnosing acute HIV infection. <i>Expert Review of Anti-Infective Therapy</i> , 2012, 10, 31-41.	2.0	14
137	Intermittent therapy for the treatment of chronic HIV infection. <i>Aids</i> , 2007, 21, 123-134.	1.0	13
138	No patient left behindâ€”better treatments for resistant HIV infection. <i>Lancet, The</i> , 2007, 370, 3-5.	6.3	13
139	Shifts in cell-associated HIV-1 RNA but not in episomal HIV-1 DNA correlate with new cycles of HIV-1 infection in vivo. <i>Antiviral Therapy</i> , 2003, 8, 97-104.	0.6	13
140	Structured treatment interruptions in HIV infection: benefit or disappointment?. <i>Expert Review of Anti-Infective Therapy</i> , 2003, 1, 129-139.	2.0	12
141	HIV-1 Genital Shedding in HIV-Infected Patients Randomized to Second-Line Lopinavir/Ritonavir Monotherapy versus Tenofovir/Lamivudine/Lopinavir/ Ritonavir. <i>Antiviral Therapy</i> , 2014, 19, 579-586.	0.6	11
142	Long-Term Virological Response to Multiple Sequential Regimens of Highly Active Antiretroviral Therapy for HIV Infection. <i>Antiviral Therapy</i> , 2004, 9, 263-274.	0.6	11
143	Article Commentary: HIV Transmission Hunting â€” the Chase for Low Risk Events. <i>Antiviral Therapy</i> , 2008, 13, 641-642.	0.6	11
144	Viral Rebound Kinetics Correlate with Distinct HIV Antibody Features. <i>MBio</i> , 2021, 12, .	1.8	10

#	ARTICLE	IF	CITATIONS
145	Virological and immunological responses to efavirenz or boosted lopinavir as first-line therapy for patients with HIV. <i>Antiviral Therapy</i> , 2009, 14, 771-779.	0.6	9
146	Interrupting highly active antiretroviral therapy in patients with HIV. <i>Expert Review of Anti-Infective Therapy</i> , 2005, 3, 51-60.	2.0	7
147	Antiretroviral treatment and research in resource-poor countries. <i>Lancet, The</i> , 2003, 361, 434-435.	6.3	6
148	Health perceptions of African HIV-infected patients and their physicians. <i>Patient Education and Counseling</i> , 2010, 80, 185-190.	1.0	6
149	Switch to etravirine for HIV-positive patients receiving statin treatment: a prospective study. <i>European Journal of Clinical Investigation</i> , 2015, 45, 720-730.	1.7	5
150	Saquinavir Trough Concentration before and after Switching Nrti to Tenofovir in Patients Treated with Once-Daily Saquinavir Hard Gel Capsule/Ritonavir 1600 Mg/100 Mg. <i>Antiviral Therapy</i> , 2004, 9, 1035-1036.	0.6	5
151	HIV-associated neurocognitive disorders: a changing pattern. <i>Future Neurology</i> , 2011, 6, 81-95.	0.9	4
152	Discontinuation of Enfuvirtide in Heavily Pretreated HIV-Infected Individuals. <i>HIV Clinical Trials</i> , 2009, 10, 207-214.	2.0	3
153	Supersensitive Viral Load Assay in Predicting CD4-Guided Treatment Failure. <i>The Open Virology Journal</i> , 2008, 2, 69-73.	1.8	1
154	Kidney light chain disease in patients with the acquired immunodeficiency syndrome. <i>CKJ: Clinical Kidney Journal</i> , 2012, 5, 59-62.	1.4	0
155	Primary HIV infection. , 2010, , 954-957.		0
156	Is autovaccination dead?. <i>Research Initiative, Treatment Action: RITA</i> , 2003, 9, 16.	0.1	0